Tositumomab Side Effects
Applies to tositumomab: intravenous kit
Common (1% to 10%): Hypothyroidism[Ref]
Common (1% to 10%): Allergic (hypersensitivity) reactions (allergic reaction, facial edema, injection site hypersensitivity, anaphylactic reaction, laryngismus, serum sickness)
Postmarketing reports: Hypersensitivity reactions including fatal anaphylaxis[Ref]
Very common (10% or more): Positive serology for human anti-mouse antibodies (HAMA)[Ref]
Frequency not reported: Infusion reactions[Ref]
Common (1% to 10%): Secondary malignancies (non-melanoma skin, colorectal, head and neck, breast, lung, bladder, melanoma, gastric)
Frequency not reported: Secondary leukemia, myelodysplastic syndrome[Ref]
1. "Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab)." GlaxoSmithKline, Research Triangle Park, NC.
2. "Product Information. BexxarTherapy (tositumomab)." GlaxoSmithKline Inc, Oakville, IA.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.